

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6080830

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ACTELION PHARMACEUTICALS LTD	02/21/2019
RECEIVING PARTY DATA		
Name:	IDORSIA PHARMACEUTICALS LTD	
Street Address:	HEGENHEIMERMATTWEG 91	
City:	ALLSCHWIL	
State/Country:	SWITZERLAND	
Postal Code:	4123	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16335973
CORRESPONDENCE DATA		
Fax Number:	(973)912-5236	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	973-912-5232	
Email:	File@hoxpat.com	
Correspondent Name:	HOXIE & ASSOCIATES LLC	
Address Line 1:	75 MAIN STREET	
Address Line 2:	SUITE 203	
Address Line 4:	MILLBURN, NEW JERSEY 07041	
ATTORNEY DOCKET NUMBER:	IDP-55-US	
NAME OF SUBMITTER:	MICHAEL J. TSIMARAS	
SIGNATURE:	/Michael J. Tsimaras/	
DATE SIGNED:	04/28/2020	
Total Attachments: 2		
source=IDP-55-US_Executed_Conf-Assignment_AC_to_IDP#page1.tif		
source=IDP-55-US_Executed_Conf-Assignment_AC_to_IDP#page2.tif		

CONFIRMATORY PATENT ASSIGNMENT

This Confirmatory Patent Assignment (this "Assignment") by ACTELION PHARMACEUTICALS LTD, Gewerbestrasse 16, 4123 Allschwil, Switzerland (the "Assignor") to IDORSIA PHARMACEUTICALS LTD, Hegenheimerweg 91, 4123 Allschwil, Switzerland (the "Assignee"), hereby confirms the prior assignment of the entire right, title, and interest in and to the below identified invention, and in and to all applications for Letters Patent on such invention and the Letters Patents to be issued on said invention, in any and all countries of the world, including the United States of America, pursuant to a transfer from the Assignor to the Assignee of the Assignor's drug discovery and early stage clinical pipeline business to Assignee, pursuant to an agreement dated 26 January 2017, and effective as of **15 June 2017** (the "Demerger Agreement").

WHEREAS, the below-identified invention was first conceived or made at a time when the inventor(s) of the below-identified invention were employed by the Assignor, and pursuant to their employment agreement(s) and obligations under Swiss law, the inventor(s) of the below-identified invention were obligated to transfer and did transfer and assign to the Assignor all right, title and interest in and to their inventions, including the below-identified invention, and

WHEREAS, the Assignor and the Assignee have determined and agreed that the below-identified invention was included in the assets transferred to the Assignee pursuant to the Demerger Agreement,

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor hereby confirms having assigned, transferred, conveyed, and delivered to the Assignee, its successors and assigns, all right, title, and interest of the Assignor in and to the invention(s) entitled

[Title of
Invention]

CRYSTALLINE FORMS

PCT Application No.: PCT/EP2017/073858

filed on: September 21, 2017

invented by: Daniel LEUENBERGER, Stefan REBER, Markus VON RAUMER

claiming priority of PCT Priority Application No.: PCT/EP2016/072562

filed on: September 22, 2016

together with all right, title and interest in and to such application, including the right to claim priority therefrom, and all applications and patents that claim priority from such application, or common priority therewith, including all divisions, continuations, continuations-in-part, substitutions, registrations, and renewals thereof, and all Letters Patent which may be granted thereon, and all reissues, reexaminations, extensions, and Supplementary Protection Certificates or the like thereof, for the entire term thereof, the same to be held and enjoyed by the Assignee for its own use and enjoyment and for the use and enjoyment of its successors, assigns and other legal representatives, as fully and entirely as the same would have been held and enjoyed by the Assignor (the Patent Rights”).

The Assignor hereby authorizes and requests the Director of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment.

IN WITNESS WHEREOF, the undersigned affirm the above to be true, to the best of their knowledge, information and belief, and have caused this Confirmatory Patent Assignment to be duly executed and delivered, effective as of **15 June 2017**.

ACTELION PHARMACEUTICALS LTD (Assignor)


By:

By:

Name and Title of First Signatory:


Thomas Gschwend

Name and Title of Second Signatory:


~~Deputy Chief Patent Counsel~~

Dr. Frank Schager
European Patent Attorney
Chief Patent Counsel

Date:


21.02.2019


IDORSIA PHARMACEUTICALS LTD (Assignee)

By:

By:

Name and Title of First Signatory:


Dr. Jörg Velker


Dr. Ralf Koberstein

Name and Title of Second Signatory:

Chief Patent Counsel

Deputy Chief Patent Counsel

Date:

February 1, 2019